HomeQuestion

For patients with stage I NSCLC, do you use RiskReveal, and if so, how do you use it to guide treatment?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Would you continue tarlatamab in CNS-only progression of small cell cancer if there is no systemic disease?

How would you manage a patient with metastatic NSCLC and high-level MET amplification who achieved a near CR on tepotinib but is unable to tolerate dose-reduced tepotinib?

Do you offer consolidation durvalumab in a patient who had pneumonitis requiring steroids following chemoradiation for LS-SCLC?

How would you sequence/prioritize therapy for a patient with newly diagnosed large but relatively asymptomatic, limited small cell lung carcinoma of the lung with newly diagnosed partially obstructing ascending colon cancer with multiple large liver metastases confirmed to be of colon origin?

How would you approach the management of a patient with metastatic non‑small cell lung cancer who previously received whole brain radiation therapy three years ago and now presents with 20 new brain metastases on MRI?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.